Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2013

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI

Résumé

The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02440743 , version 1 (15-01-2020)

Identifiants

Citer

Marie Vincent, Agnès Quéméner, Yannick Jacques. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. OncoImmunology, 2013, ⟨10.4161/onci.26441⟩. ⟨inserm-02440743⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More